Articles

Outcomes after extracorporeal life support for COVID-19 myocarditis: an analysis of the Extracorporeal Life Support Organization Registry

Tonna, Joseph E.; Tan, Chuen S.; Hryniewicz, Kasia; Barbaro, Ryan P.; Brodie, Daniel; MacLaren, Graeme

First described early in the pandemic, coronavirus disease 2019 (COVID-19)-associated fulminant myocarditis can present with arrhythmias and cardiogenic shock, but may be treatable with mechanical circulatory support, such as venoarterial (VA) extracorporeal life support (ECLS) [1]. To better characterize severe myocarditis during the COVID-19 pandemic, we analyzed adult patients with severe COVID-19 who received ECLS for cardiac, pulmonary, or combined failure using an international registry.

Subjects

Files

  • thumnail for 13054_2022_Article_4111.pdf 13054_2022_Article_4111.pdf application/pdf 138 KB

Also Published In

Title
Critical Care
DOI
https://doi.org/10.1186/s13054-022-04111-z

More About This Work

Published Here
July 22, 2024

Related Items

Identical to:
Outcomes after extracorporeal life support for COVID-19 myocarditis: an analysis of the Extracorporeal Life Support Organization Registry

Notes

Cardiac failure, Respiratory failure, Acute respiratory distress syndrome, Myocardial inflammation